Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Complement System: a Neglected Pathway in Immunotherapy.

Bordron A, Bagacean C, Tempescul A, Berthou C, Bettacchioli E, Hillion S, Renaudineau Y.

Clin Rev Allergy Immunol. 2019 May 29. doi: 10.1007/s12016-019-08741-0. [Epub ahead of print] Review.

PMID:
31144209
2.

STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia.

Debant M, Burgos M, Hemon P, Buscaglia P, Fali T, Melayah S, Le Goux N, Vandier C, Potier-Cartereau M, Pers JO, Tempescul A, Berthou C, Bagacean C, Mignen O, Renaudineau Y.

J Immunother Cancer. 2019 Apr 23;7(1):111. doi: 10.1186/s40425-019-0591-3.

3.

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Pertesi M, Vallée M, Wei X, Revuelta MV, Galia P, Demangel D, Oliver J, Foll M, Chen S, Perrial E, Garderet L, Corre J, Leleu X, Boyle EM, Decaux O, Rodon P, Kolb B, Slama B, Mineur P, Voog E, Le Bris C, Fontan J, Maigre M, Beaumont M, Azais I, Sobol H, Vignon M, Royer B, Perrot A, Fuzibet JG, Dorvaux V, Anglaret B, Cony-Makhoul P, Berthou C, Desquesnes F, Pegourie B, Leyvraz S, Mosser L, Frenkiel N, Augeul-Meunier K, Leduc I, Leyronnas C, Voillat L, Casassus P, Mathiot C, Cheron N, Paubelle E, Moreau P, Bignon YJ, Joly B, Bourquard P, Caillot D, Naman H, Rigaudeau S, Marit G, Macro M, Lambrecht I, Cliquennois M, Vincent L, Helias P, Avet-Loiseau H, Moreno V, Reis RM, Varkonyi J, Kruszewski M, Vangsted AJ, Jurczyszyn A, Zaucha JM, Sainz J, Krawczyk-Kulis M, Wątek M, Pelosini M, Iskierka-Jażdżewska E, Grząśko N, Martinez-Lopez J, Jerez A, Campa D, Buda G, Lesueur F, Dudziński M, García-Sanz R, Nagler A, Rymko M, Jamroziak K, Butrym A, Canzian F, Obazee O, Nilsson B, Klein RJ, Lipkin SM, McKay JD, Dumontet C.

Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0452-6. [Epub ahead of print] No abstract available.

PMID:
30967618
4.

Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives.

Bagacean C, Tomuleasa C, Tempescul A, Grewal R, Brooks WH, Berthou C, Renaudineau Y.

Crit Rev Clin Lab Sci. 2019 Apr 2:1-12. doi: 10.1080/10408363.2019.1600468. [Epub ahead of print]

PMID:
30935269
5.

Rapid and complete response to idelalisib in a case of Richter syndrome.

Bagacean C, Zdrenghea M, Saad H, Berthou C, Renaudineau Y, Tempescul A.

Onco Targets Ther. 2019 Feb 13;12:1181-1184. doi: 10.2147/OTT.S187459. eCollection 2019.

6.

The regulatory capacity of B cells directs the aggressiveness of CLL.

Mohr A, Cumin M, Bagacean C, Pochard P, Le Dantec C, Hillion S, Renaudineau Y, Berthou C, Tempescul A, Saad H, Pers JO, Bordron A, Jamin C.

Oncoimmunology. 2018 Dec 12;8(3):1554968. doi: 10.1080/2162402X.2018.1554968. eCollection 2019.

PMID:
30723588
7.

17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.

Bagacean C, Tempescul A, Ternant D, Banet A, Douet-Guilbert N, Bordron A, Bendaoud B, Saad H, Zdrenghea M, Berthou C, Paintaud G, Renaudineau Y.

J Immunother Cancer. 2019 Jan 29;7(1):22. doi: 10.1186/s40425-019-0509-0.

8.

Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy.

Bordron A, Bagacean C, Mohr A, Tempescul A, Bendaoud B, Deshayes S, Dalbies F, Buors C, Saad H, Berthou C, Pers JO, Renaudineau Y.

Oncotarget. 2018 Aug 3;9(60):31590-31605. doi: 10.18632/oncotarget.25657. eCollection 2018 Aug 3.

9.

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Durán MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbényi Z, Abadi U, Pedersen RS, Černelč P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M; EMMOS Investigators.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e401-e419. doi: 10.1016/j.clml.2018.06.018. Epub 2018 Jun 25.

10.

High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.

Avivi I, Arcaini L, Ferretti VV, Boumendil A, Finel H, Milone G, Zaja F, Liliana D, Musso M, Didier B, Bachy E, Wattad M, Nicolas-Virelizier E, Gramatzki M, Bourhis JH, Caillot D, Haenel A, Held G, Thieblemont C, Jindra P, Pohlreich D, Guilhot F, Kroschinsky F, Wahlin B, Scheid C, Ifrah N, Berthou C, Dreger P, Montoto S, Conconi A.

Br J Haematol. 2018 Sep;182(6):807-815. doi: 10.1111/bjh.15454. Epub 2018 Jul 9.

PMID:
29984825
11.

Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.

Mollard LM, Chauveau A, Boyer-Perrard F, Douet-Guilbert N, Houot R, Quintin-Roué I, Couturier MA, Dagorne A, Malou M, Le Calloch R, Luycx O, Thepot S, Hunault M, Guillerm G, Berthou C, Ugo V, Lippert É, Ianotto JC.

Leuk Lymphoma. 2018 Dec;59(12):2812-2820. doi: 10.1080/10428194.2018.1441408. Epub 2018 Apr 4.

PMID:
29616837
12.

Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation.

Avivi I, Boumendil A, Finel H, Nagler A, de Sousa AB, Santasusana JMR, Vandenberghe E, Afanasyev B, Bordessoule D, Moraleda JM, Garcia EC, Pohlreich D, Garcia GG, Thomson K, Or R, Beelen D, Zuffa E, Giebel S, Berthou C, Salles G, Melpignano A, Montoto S, Dreger P.

Bone Marrow Transplant. 2018 Aug;53(8):1001-1009. doi: 10.1038/s41409-017-0063-7. Epub 2018 Feb 20.

PMID:
29463854
13.

Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.

Le Clech L, Talarmin JP, Couturier MA, Ianotto JC, Nicol C, Le Calloch R, Dos Santos S, Hutin P, Tandé D, Cogulet V, Berthou C, Guillerm G.

Infect Dis (Lond). 2018 Jul;50(7):539-549. doi: 10.1080/23744235.2018.1438649. Epub 2018 Feb 16.

PMID:
29451055
14.

DNA demethylation marks in chronic lymphocytic leukemia: it is time to let the cat out of the bag.

Bagacean C, Zdrenghea M, Dantec CL, Tempescul A, Berthou C, Renaudineau Y.

Future Sci OA. 2017 Nov 3;4(2):FSO265. doi: 10.4155/fsoa-2017-0120. eCollection 2018 Feb. No abstract available.

15.

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.

Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO).

Lancet Haematol. 2018 Feb;5(2):e82-e94. doi: 10.1016/S2352-3026(17)30235-1. Epub 2017 Dec 20.

PMID:
29275118
16.

Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).

Le Calloch R, Lacut K, Le Gall-Ianotto C, Nowak E, Abiven M, Tempescul A, Dalbies F, Eveillard JR, Ugo V, Giraudier S, Guillerm G, Lippert E, Berthou C, Ianotto JC.

Haematologica. 2018 Apr;103(4):607-613. doi: 10.3324/haematol.2017.180448. Epub 2017 Dec 15.

17.

Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion.

Bagacean C, Le Dantec C, Berthou C, Tempescul A, Saad H, Bordron A, Zdrenghea M, Cristea V, Douet-Guilbert N, Renaudineau Y.

Clin Epigenetics. 2017 Nov 28;9:122. doi: 10.1186/s13148-017-0422-7. eCollection 2017.

18.

Incidence and impact of atrial arrhythmias on thrombotic events in MPNs.

Mahé K, Delluc A, Chauveau A, Castellant P, Mottier D, Dalbies F, Berthou C, Guillerm G, Lippert E, Ianotto JC.

Ann Hematol. 2018 Jan;97(1):101-107. doi: 10.1007/s00277-017-3164-x. Epub 2017 Nov 21.

PMID:
29164292
19.

Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia.

Bagacean C, Tempescul A, Le Dantec C, Bordron A, Mohr A, Saad H, Olivier V, Zdrenghea M, Cristea V, Cartron PF, Douet-Guilbert N, Berthou C, Renaudineau Y.

Oncotarget. 2017 Aug 9;8(39):65699-65716. doi: 10.18632/oncotarget.20081. eCollection 2017 Sep 12.

20.

Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms.

Ianotto JC, Couturier MA, Galinat H, Mottier D, Berthou C, Guillerm G, Lippert E, Delluc A.

Int J Hematol. 2017 Oct;106(4):517-521. doi: 10.1007/s12185-017-2282-5. Epub 2017 Jun 16.

PMID:
28623609
21.

The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes.

Le Clech L, Sakka M, Meskar A, Kerspern H, Eveillard JR, Berthou C, Buors C, Lippert E, Guillerm G, Quintin-Roué I, Carré JL, Ianotto JC.

Leuk Lymphoma. 2017 Nov;58(11):2582-2587. doi: 10.1080/10428194.2017.1312380. Epub 2017 May 9.

PMID:
28482711
22.

Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only.

Nicol C, Henry C, Couturier MA, Delépine P, Tripogney C, Buors C, Guillerm G, Berthou C, Tempescul A, Ianotto JC.

Leuk Lymphoma. 2017 Sep;58(9):1-3. doi: 10.1080/10428194.2017.1285025. Epub 2017 Feb 7. No abstract available.

PMID:
28278727
23.

Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.

Pigneux A, Béné MC, Guardiola P, Recher C, Hamel JF, Sauvezie M, Harousseau JL, Tournilhac O, Witz F, Berthou C, Escoffre-Barbe M, Guyotat D, Fegueux N, Himberlin C, Hunault M, Delain M, Lioure B, Jourdan E, Bauduer F, Dreyfus F, Cahn JY, Sotto JJ, Ifrah N.

J Clin Oncol. 2017 Feb;35(4):387-393. doi: 10.1200/JCO.2016.67.6213. Epub 2016 Oct 24.

PMID:
28129526
24.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P.

Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8.

PMID:
27964867
25.

Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus Rituximab: comparison between Deauville 5-point scale and International Harmonization Project criteria.

Lombion N, Robin P, Tempescul A, LE Roux PY, Schick U, Guillerm G, Ianotto JC, Berthou C, Salaün PY, Abgral R.

Q J Nucl Med Mol Imaging. 2016 Nov 30. [Epub ahead of print]

PMID:
27901328
26.

JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort.

Ianotto JC, Chauveau A, Mottier D, Ugo V, Berthou C, Lippert E, Delluc A.

Ann Hematol. 2017 Mar;96(3):383-386. doi: 10.1007/s00277-016-2853-1. Epub 2016 Oct 20.

PMID:
27766390
27.

CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes.

Garaud S, Taher TE, Debant M, Burgos M, Melayah S, Berthou C, Parikh K, Pers JO, Luque-Paz D, Chiocchia G, Peppelenbosch M, Isenberg DA, Youinou P, Mignen O, Renaudineau Y, Mageed RA.

Cell Mol Immunol. 2018 Feb;15(2):158-170. doi: 10.1038/cmi.2016.42. Epub 2016 Aug 8.

28.

Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms.

Le Gall-Ianotto C, Brenaut E, Gouillou M, Lacut K, Nowak E, Tempescul A, Berthou C, Ugo V, Carré JL, Misery L, Ianotto JC.

Br J Dermatol. 2017 Jan;176(1):255-258. doi: 10.1111/bjd.14809. Epub 2016 Dec 22. No abstract available.

PMID:
27291777
29.

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.

Rousselot P, Coudé MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Chevallier P, Salanoubat C, Bonmati C, Alexis M, Hunault M, Glaisner S, Agape P, Berthou C, Jourdan E, Fernandes J, Sutton L, Banos A, Reman O, Lioure B, Thomas X, Ifrah N, Lafage-Pochitaloff M, Bornand A, Morisset L, Robin V, Pfeifer H, Delannoy A, Ribera J, Bassan R, Delord M, Hoelzer D, Dombret H, Ottmann OG; European Working Group on Adult ALL (EWALL) group.

Blood. 2016 Aug 11;128(6):774-82. doi: 10.1182/blood-2016-02-700153. Epub 2016 Apr 27.

30.

Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.

Golay J, Choblet S, Iwaszkiewicz J, Cérutti P, Ozil A, Loisel S, Pugnière M, Ubiali G, Zoete V, Michielin O, Berthou C, Kadouche J, Mach JP, Duonor-Cérutti M.

J Immunol. 2016 Apr 1;196(7):3199-211. doi: 10.4049/jimmunol.1501592. Epub 2016 Feb 26.

31.

Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 (V617F) and JAK2 exon 12 allele burden disappearance during the follow-up of two patients.

Mahé K, Luque Paz D, Couturier MA, Chauveau A, Quintin-Roué I, Berthou C, Ugo V, Lippert E, Ianotto JC.

Ann Hematol. 2016 Feb;95(3):529-31. doi: 10.1007/s00277-015-2559-9. Epub 2015 Nov 27. No abstract available.

PMID:
26611851
32.

ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases.

Ungur R, Tempescul A, Berthou C, Bagacean C, Radeanu D, Muresan A, Zdrenghea M.

Onco Targets Ther. 2015 Oct 1;8:2771-3. doi: 10.2147/OTT.S89358. eCollection 2015.

33.

Encephalitozoon hellem in a patient with CD4+ T-cell prolymphocytic leukemia: case report and genomic identification.

Nevez G, Le Gal S, Quinio D, Ianotto JC, Berthou C, Hamane S, Sarfati C, Menotti J.

Diagn Microbiol Infect Dis. 2015 Nov;83(3):245-7. doi: 10.1016/j.diagmicrobio.2015.07.015. Epub 2015 Jul 26.

PMID:
26299583
34.

Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism.

Ianotto JC, Chauveau A, Luque Paz D, Delluc A, Tromeur C, Couturier MA, Gouillou M, Berthou C, Mottier D, Ugo V.

Thromb Haemost. 2016 Jan;115(1):225-6. doi: 10.1160/TH15-02-0134. Epub 2015 Aug 20. No abstract available.

PMID:
26290216
35.

Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines.

Troadec S, Blairvacq M, Oumata N, Galons H, Meijer L, Berthou C.

J Biomed Sci. 2015 Jul 17;22:57. doi: 10.1186/s12929-015-0163-x.

36.

Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.

Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Leprêtre S, Dilhuydy MS, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, De Guibert S, Aurran T, Laribi K, Vilque JP, Tournilhac O, Delmer A, Feugier P, Cazin B, Michallet AS, Lévy V, Troussard X, Delepine R, Tavernier E, Colombat P, Leblond V.

Leuk Lymphoma. 2016 Feb;57(2):328-334. doi: 10.3109/10428194.2015.1063139. Epub 2015 Sep 28.

PMID:
26140301
37.

Ofatumumab in a chronic lymphocytic leukemia patient with graft versus host disease and relapse after mini-allo BMT.

Urian L, Renaudineau Y, Berthou C, Zdrenghea M, Petrov L, Tempescul A.

J BUON. 2015 Mar-Apr;20(2):668-9. No abstract available.

38.

A new point mutation in EPOR inducing a short deletion in congenital erythrocytosis.

Chauveau A, Luque Paz D, Lecucq L, Le Gac G, Le Maréchal C, Gueguen P, Berthou C, Ugo V.

Br J Haematol. 2016 Feb;172(3):475-7. doi: 10.1111/bjh.13511. Epub 2015 May 26. No abstract available.

PMID:
26010769
39.

Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion.

Tempescul A, Bagacean C, Riou C, Bendaoud B, Hillion S, Debant M, Buors C, Berthou C, Renaudineau Y.

Eur J Haematol. 2016 Mar;96(3):229-35. doi: 10.1111/ejh.12573. Epub 2015 May 20.

PMID:
25911969
40.

Growth deceleration in children treated with imatinib for chronic myeloid leukaemia.

Millot F, Guilhot J, Baruchel A, Petit A, Leblanc T, Bertrand Y, Mazingue F, Lutz P, Vérité C, Berthou C, Galambrun C, Nicolas Sirvent, Yacouben K, Chastagner P, Gandemer V, Reguerre Y, Couillault G, Khalifeh T, Rialland F.

Eur J Cancer. 2014 Dec;50(18):3206-11.

PMID:
25459396
41.

An eIF4E-interacting peptide induces cell death in cancer cell lines.

Masse M, Glippa V, Saad H, Le Bloas R, Gauffeny I, Berthou C, Czjzek M, Cormier P, Cosson B.

Cell Death Dis. 2014 Oct 30;5:e1500. doi: 10.1038/cddis.2014.457.

42.

Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study.

Millot F, Guilhot J, Baruchel A, Petit A, Bertrand Y, Mazingue F, Lutz P, Vérité C, Berthou C, Galambrun C, Sirvent N, Yakouben K, Schmitt C, Gandemer V, Reguerre Y, Couillault G, Mechinaud F, Cayuela JM.

Blood. 2014 Oct 9;124(15):2408-10. doi: 10.1182/blood-2014-05-578567. Epub 2014 Aug 28.

43.

The arachidonic acid-LTB4-BLT2 pathway enhances human B-CLL aggressiveness.

Guriec N, Le Jossic-Corcos C, Simon B, Ianotto JC, Tempescul A, Dréano Y, Salaün JP, Berthou C, Corcos L.

Biochim Biophys Acta. 2014 Nov;1842(11):2096-105. doi: 10.1016/j.bbadis.2014.07.016. Epub 2014 Jul 26.

44.

Exopolysaccharides isolated from hydrothermal vent bacteria can modulate the complement system.

Courtois A, Berthou C, Guézennec J, Boisset C, Bordron A.

PLoS One. 2014 Apr 15;9(4):e94965. doi: 10.1371/journal.pone.0094965. eCollection 2014.

45.

Dissociated evolution of a multifocal primary CNS lymphoma.

Bagacean C, Zdrenghea M, Popescu C, Quintin-Roue I, Ianotto JC, Eveillard JR, Berthou C, Tempescul A.

J BUON. 2013 Oct-Dec;18(4):1098. No abstract available.

46.

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.

Kamioner D, Fruehauf S, Maloisel F, Cals L, Lepretre S, Berthou C.

BMC Cancer. 2013 Nov 16;13:547. doi: 10.1186/1471-2407-13-547.

47.

Pneumocystis jirovecii haplotypes at the internal transcribed spacers of the rRNA operon in French HIV-negative patients with diverse clinical presentations of Pneumocystis infections.

Le Gal S, Rouille A, Gueguen P, Virmaux M, Berthou C, Guillerm G, Couturaud F, Le Meur Y, Damiani C, Totet A, Nevez G.

Med Mycol. 2013 Nov;51(8):851-62. doi: 10.3109/13693786.2013.824123. Epub 2013 Aug 22.

PMID:
23964829
48.

Long-term remission of T-cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy.

Cornec D, Devauchelle-Pensec V, Jousse-Joulin S, Marhadour T, Ugo V, Berthou C, Douet-Guilbert N, Saraux A.

Blood. 2013 Aug 29;122(9):1583-6. doi: 10.1182/blood-2013-03-491464. Epub 2013 Jul 18.

49.

Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery.

Ianotto JC, Ngo Sack F, Couturier MA, Tempescul A, Mugnier N, Delepine P, Guillerm G, Berthou C.

Leuk Lymphoma. 2014 Jan;55(1):74-7. doi: 10.3109/10428194.2013.791984. Epub 2013 Jun 5.

PMID:
23566160
50.

Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.

Cosimo E, McCaig AM, Carter-Brzezinski LJ, Wheadon H, Leach MT, Le Ster K, Berthou C, Durieu E, Oumata N, Galons H, Meijer L, Michie AM.

Clin Cancer Res. 2013 May 1;19(9):2393-405. doi: 10.1158/1078-0432.CCR-12-2170. Epub 2013 Mar 26.

Supplemental Content

Loading ...
Support Center